StockData
Biodexa Pharmaceuticals Plc logo

Biodexa Pharmaceuticals Plc (BDRX) stock

BDRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Mar 27, 2026Score 1/30
$2.14−0.10 (-4.46%)

Close on Nov 17, 2026Market cap $4.83MP/E –Yield –

Biodexa Pharmaceuticals r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was £3.96M, down 27.1% from the year before. Over ten years it grew -7.6% a year on average. The highest annual figure on record is £9.36M in fiscal 2018.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025£3.96M-27.1%
FY2024Dec 31, 2024£5.44M+33.7%
FY2023Dec 31, 2023£4.07M-20.4%
FY2022Dec 31, 2022£5.11M+9.8%
FY2021Dec 31, 2021£4.65M-23.3%
FY2020Dec 31, 2020£6.07M-22.6%
FY2019Dec 31, 2019£7.84M-16.2%
FY2018Dec 31, 2018£9.36M+12.4%
FY2017Dec 31, 2017£8.33M+7.7%
FY2016Dec 31, 2016£7.73M-11.3%
FY2015Dec 31, 2015£8.71M–

More Biodexa Pharmaceuticals figures

See a number that looks wrong?